Lumos Pharma Gets $34M In Series B Funding

Austin-based Lumos Pharma, a developer of treatments for rare and genetic diseases, said todayt hat it has raised $34M in a Series B funding round. The funding was led by Deerfield Management Company, and also included Clarus Ventures, Roche Venture Fund, New Enterprise Associates (NEA), Sante Ventures and Belgian pharmaceutical UCB. The company said the funding goes towards its lead compound, LUM-001, as well as further developing other therapeutics in its pipeline. Lumos is led by Rick Hawkins. LUM-001 is aied at treating Creatine Transporter Deficiency (CTD). More information »